Significant research to evaluate treatments for neurological disorders is underway at Renown including studies relevant to multiple sclerosis, stroke and epilepsy. Here are some highlights:
A research study sponsored by Berlex Laboratories with 2100 individual subjects in 190 separate sites around the world. The title of the study is a International, randomized multicenter, phase IIIb study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks.
In brief, patients in this study have been diagnosed with relapsing-remitting multiple sclerosis (RRMS), are between the ages of 18 and 55, and have met other inclusion rules. The purpose of this study is to evaluate the safety and tolerability of two doses of Betaseron®(Interferon -1b) 250mg and 500mg respectively and Interferon -1b and Copaxone® Currently, this study is not accepting new patients.
G. Kim Bigley, M.D.
A research study sponsored by AstraZeneca Pharmaceuticals with currently 1800 subjects enrolled in the United States, Canada, and South America. Enrollment is ongoing with 3500 expected subjects to be participating by study end. The title of this study is a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIIb/III study to assess the efficacy and safety of intravenous (through the vein) NXY-059 in Acute Ischemic Stroke. Participation in this study will continue for approximately 3 months.
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination. Currently, we are recruiting for this study.
A research study sponsored by GlaxoSmithKline with 45 individual subjects from several different sites in the United States expected to participate. This study is titled: Open-label, double conversion study to characterize the pharmacokinetics of Lamatrigine when switching patients with Epilepsy on Lamictal Immediate-release to Extended-release formulation and vice versa. Participation in this study is 5 weeks. This study requires two 48-hour observational hospital stays. During which multiple blood draws will be done.
The purpose of this study is to determine how well seizures are controlled on Lamictal IR (immediate release) taken twice a day, compared to Lamictal ER (extended release) taken once a day. In addition, participants will be asked to participate in a Pharmacogenetic sub-study to determine if 1) there is a relationship between a participant’s genetic characteristics and his/her ability to metabolize Lamictal, and 2) if there is a relationship between a participant’s genetics and the safety and tolerability of Lamictal. Currently, we are recruiting patients into this study.